1
Views
0
CrossRef citations to date
0
Altmetric
Original Article

Cytologic changes in two cervical carcinoma cell lines after transfection of the wild-type p53 gene

, , , , &
Pages 797-803 | Received 03 Nov 1995, Accepted 24 Apr 1996, Published online: 03 Aug 2009
 

Abstract

Background. To examine morphological changes in cervical carcinoma cells after induction of overexpression of wild-type (wt) p53.

Method. A dexamethazone-inducible wt-p53 cDNA was introduced into two cervical carcinoma cell lines (TMCC-1 and ME180) and morphological changes were examined under a phase contrast microscope and following Papanicolaou staining.

Results. TMCC-1 clones obtained by transfection with wt-p53 gene had an altered morphology especially after induction of p53 expression by treatment with dexamethazone. These changes were characterized by cell flattening, multinucleation, micronucleation, and huge giant cells, yet the parental TMCC-1 had none of these morphological changes even after treatment with dexamethazone. Similar cellular changes were observed in ME 180 clones obtained by transfection of wt-p53 gene.

Conclusion. On the basis of our observations, we propose that the growth inhibition induced by expression of wt-p53 in these cervical carcinoma cell lines carrying HPV DNA sequences is not the result of G1 arrest but rather relates to a blockade in the M phase of the cell cycle.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.